NCT03302182View on ClinicalTrials.gov

Bioequivalence Study of Ritonavir Versus NORVIR in Healthy Chinese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

September 23, 2017

Primary Completion Date

November 4, 2017

Study Completion Date

December 4, 2017

Conditions
Healthy Volunteer
Interventions
DRUG

Ritonavir for cycle1 and NORVIR for cycle 2

During the study session, healthy subjects will be administered a single dose of Ritonavir Tablet 100mg in cycle 1 and NORVIR tablet 100mg in cycle 2 .

DRUG

NORVIR for cycle 1 and Ritonavir for cycle 2

During the study session, healthy subjects will be administered a single dose of NORVIR Tablet 100mg in cycle 1 and Ritonavir tablet 100mg in cycle 2 .

Trial Locations (1)

310003

First affiliated hospital of Zhejiang University, Hangzhou

Sponsors
All Listed Sponsors
collaborator

Ascletis Pharmaceuticals Co., Ltd.

INDUSTRY

lead

First Affiliated Hospital of Zhejiang University

OTHER